drugset / Trial / NCT03471767

AXS-05 Phase II Trial on Smoking Behavior

NCT03471767

Phase 2 Completed 58 enrolled James Davis Axsome Therapeutics, Inc. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This research study is designed with the purpose of evaluating a new drug, combination Dextromethorphan-Bupropion (AXS-05), for its effects on smoking behavior.

Timeline

Start
2018-03-25
Primary completion
2019-03-31
Completion
2019-03-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bupropion Small molecule Oral
Subject Dextromethorphan Unknown Oral

Indications